Bioray Biotech Co., Ltd (TPEX:7561)
Taiwan · Delayed Price · Currency is TWD 23.85
-0.05 (-0.21%)
At close: Feb 6, 2026
Bioray Biotech Revenue
Bioray Biotech had revenue of 114.14M TWD in the half year ending June 30, 2025, with 21.35% growth. This brings the company's revenue in the last twelve months to 230.06M, up 25.32% year-over-year. In the year 2024, Bioray Biotech had annual revenue of 201.71M with 5.15% growth.
Revenue (ttm)
230.06M
Revenue Growth
+25.32%
P/S Ratio
3.07
Revenue / Employee
n/a
Employees
n/a
Market Cap
705.61M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 201.71M | 9.88M | 5.15% |
| Dec 31, 2023 | 191.83M | 1.23M | 0.65% |
| Dec 31, 2022 | 190.60M | 42.58M | 28.77% |
| Dec 31, 2021 | 148.02M | -8.28M | -5.30% |
| Dec 31, 2020 | 156.30M | -25.64M | -14.09% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Anxo Pharmaceutical | 883.22M |
| Excelsior Biopharma | 859.77M |
| Prince Pharmaceutical | 798.27M |
| Winston Medical Supply | 724.35M |
| DV Biomed | 712.61M |
| Tien Liang BioTech | 467.02M |
| General Biologicals | 251.38M |
| Mediera | 240.30M |